NCT07276542: Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.

Sponsor: The Ketamine Research Foundation. Phase: PHASE2. Conditions: Phantom Limb Syndrome With Pain